Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8438238 | 1.00 | FNTA (0.37) | FNTAFNTBTHRBPGGT1BLMNA | |
| SCHEMBL4988237 | 1.00 | FNTA (0.37) | FNTAFNTBTHRBPGGT1BLMNA | |
| Methacrylic Acid SCHEMBL29808091 | 0.91 | THRB (0.32) | FNTAFNTBTHRBPGGT1B | |
| SCHEMBL715889 | 0.80 | GPR84 (0.52) | FNTAFNTBTHRBPGGT1BLMNA | |
| SCHEMBL3841640 | 0.78 | HDAC3 (0.48) | FNTAFNTBTHRBPGGT1BALDH1A1 | |
| SCHEMBL811388 | 0.78 | LMNA (0.52) | FNTAFNTBTHRBPGGT1BLMNA | |
| SCHEMBL21044318 | 0.78 | LMNA (0.33) | LMNASLC15A2ALDH1A1CAMK2AFFAR3 | |
| SCHEMBL21044316 | 0.78 | LMNA (0.33) | LMNASLC15A2ALDH1A1CAMK2AFFAR3 | |
| SCHEMBL3841638 | 0.78 | HDAC3 (0.48) | FNTAFNTBTHRBPGGT1BALDH1A1 | |
| SCHEMBL28382991 | 0.78 | FNTA (0.37) | FNTAFNTBTHRBPGGT1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318473-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | ABRAXIS BIOSCIENCE LLC (US) | 2018-11-08 | — | — | US | claimed |
| EP-3345631-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | Abraxis BioScience, LLC (US) | 2018-07-11 | — | — | EP | claimed |
| EP-3345632-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | Abraxis BioScience, LLC (US) | 2018-07-11 | — | — | EP | claimed |
| US-9982184-B2 | Terpolymer compositions | EVONIK CORPORATION (US) | 2018-05-29 | — | — | US | claimed |
| US-9954126-B2 | Three-dimensional photovoltaic devices including cavity-containing cores and methods of manufacture | Q1 NANOSYSTEMS CORPORATION (US) | 2018-04-24 | — | — | US | claimed |
| EP-3286279-A1 | FRICTION REDUCING TERPOLYMER COMPOSITIONS AND METHOD OF FRACTURING | Evonik Corporation (US) | 2018-02-28 | — | — | EP | claimed |
| EP-1861070-B1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | ABRAXIS BIOSCIENCE LLC (US) | 2018-01-17 | — | — | EP | claimed |
| US-20170203012-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | ABRAXIS BIOSCIENCE LLC (US) | 2017-07-20 | — | — | US | claimed |
| WO-2016172067-A1 | FRICTION REDUCING TERPOLYMER COMPOSITIONS AND METHOD OF FRACTURING | EVONIK CORPORATION (US) | 2016-10-27 | — | — | WO | claimed |
| US-20160304769-A1 | TERPOLYMER COMPOSITIONS | EVONIK CORPORATION | 2016-10-20 | — | — | US | claimed |
| US-20050137684-A1 | Stent with therapeutically active drug coated thereon | PFIZER INC | 2005-06-23 | — | — | US | claimed |
| US-20050085902-A1 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures,Including delivery using a modified stent | CARDINAL HEALTH SWITZERLAND 515 GmbH (CH) | 2005-04-21 | — | — | US | claimed |
| EP-1407726-A1 | Local delivery of rapamycin for treatment of proliferative sequelae associated with PTCA procedures, including delivery using a modified stent | Cordis Corporation (US) | 2004-04-14 | — | — | EP | claimed |
| US-6585764-B2 | Stent with therapeutically active dosage of rapamycin coated thereon | CORDIS CORPORATION | 2003-07-01 | — | — | US | claimed |
| EP-0587565-B1 | INTRAOCULAR LENS WITH HAPTIC ANCHOR PLATE | MEDEVEC LICENSING BV (NL) | 1998-08-19 | — | — | EP | claimed |
| EP-0587565-A4 | INTRAOCULAR LENS WITH HAPTIC ANCHOR PLATE. | CUMMING STUART J (US) | 1995-02-22 | — | — | EP | claimed |
| EP-0587565-A1 | INTRAOCULAR LENS WITH HAPTIC ANCHOR PLATE | MEDEVEC LICENSING B.V. (NL) | 1994-03-23 | — | — | EP | claimed |
| WO-1992021304-A1 | INTRAOCULAR LENS WITH HAPTIC ANCHOR PLATE | CUMMING STUART J (US) | 1992-12-10 | — | — | WO | claimed |
| US-5047051-A | Intraocular lens with haptic anchor plate | THE NICE TRUST, A TRUST OF THE ISLE OF MAN | 1991-09-10 | — | — | US | claimed |
| EP-0274721-A2 | Polymers containing amino groups, their manufacture and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-07-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170203012-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | MIF, MKI67, ABCB11 | FNTA 1546/4885FNTB 3933/4885THRB 4027/4885 |
| US-20180318473-A1 | DRUGS WITH IMPROVED HYDROPHOBICITY FOR INCORPORATION IN MEDICAL DEVICES | MIF, MKI67, ABCB11 | FNTA 1546/4885FNTB 3933/4885THRB 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.